Company Overview
Puma Biotechnology, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of therapeutic products designed to enhance cancer care across the United States and international markets. The company specifically focuses on NERLYNX, an oral formulation of neratinib intended for adult patients with early-stage HER2-overexpressing breast cancer, representing a key asset in its oncology portfolio. Operating within the healthcare sector and the biotechnology industry, the firm navigates a landscape defined by rigorous research standards, regulatory oversight, and the high-cost nature of drug development. With a market capitalization of $322.05M, annual revenue of $228.37M, and an employee base of 179, the company maintains a lean organizational structure typical of late-stage biotech firms. These valuation and revenue figures indicate a mid-cap position that relies heavily on the successful commercialization of its pipeline to generate sustained cash flow, rather than the broad revenue diversification seen in larger pharmaceutical conglomerates.
Financial Health
The company reported revenue of $228.37M and net income of $31.11M for the trailing twelve months, while EBITDA stood at $47.44M. The significant gap between revenue and net income reveals a substantial cost structure involving operating expenses, research costs, and general administrative overheads that reduce the bottom line by approximately 86.4% before considering interest and taxes. Free cash flow is reported at $30.69M, which provides the company with essential financial flexibility to fund ongoing clinical trials, expand manufacturing capabilities, or pursue strategic acquisitions without relying on external financing. The gross margin is 74.5%, indicating high efficiency in the cost of goods sold relative to sales, while the operating margin of 22.7% and profit margin of 13.6% demonstrate the company's ability to control overhead and convert revenue into actual profit. Total cash holdings of $97.53M significantly exceed total debt of $28.55M, and with a debt-to-equity ratio of 21.90%, the balance sheet appears conservative with ample liquidity to cover obligations. The current ratio of 2.00 suggests strong short-term liquidity, as current assets are double the value of current liabilities, ensuring the firm can meet its immediate financial commitments. Furthermore, a return on equity of 28.0% and a return on assets of 10.9% indicate that management is utilizing shareholder capital and total assets effectively to generate returns, a critical metric for capital-intensive biotechnology companies.
Valuation Assessment
The trailing twelve-month P/E ratio is 10.38, while the forward P/E is projected at 9.74. The difference between these two multiples implies that the market expects earnings growth to outpace current profitability, as investors are willing to pay a lower multiple for future earnings. The price-to-book ratio is 2.45, which indicates that the market is valuing the company at a significant premium over its net asset value, reflecting the intangible value of its drug pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 1.41 and an EV/EBITDA of 5.33 suggest that the stock is priced reasonably relative to its sales volume and earnings power before interest and taxes. The 52-week high is $7.68 and the 52-week low is $2.58, meaning the current price sits within the trading range but remains below the recent peak of the year. A beta of 1.27 indicates that the stock price is more volatile than the broader market, moving with greater intensity during periods of market uncertainty or sector-specific shifts.
Growth & Income
Revenue growth year-over-year is 27.7%, whereas earnings growth year-over-year is -34.4%. This divergence implies that while top-line sales are expanding rapidly, the company is currently experiencing earnings contraction, likely due to the timing of expense recognition or the ramp-up phase of new product launches. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which means all earnings are retained within the business to fuel research and development rather than being distributed to shareholders. The absence of a dividend policy aligns with the biotechnology industry standard where capital is prioritized for reinvestment into growth opportunities rather than providing immediate income to investors. Overall, the growth and income profile is characterized by strong revenue expansion offset by temporary earnings volatility, with a strategic focus on capital retention to drive future product commercialization.